Don’t miss this webinar! Tuesday 25th March 2025
Register Your Place For
Alzheimer’s Investigator Meeting
Date and Time:
Tuesday 25th March 2025
A 6-month (stage 1) & 18-month (stage 2) prospective, randomized, placebo-controlled, doubleblind dual clinical trial investigating efficacy and safety of buntanetap in treating participants with early Alzheimer’s disease.
By registering you confirm that you have read our privacy policy.
What To Expect
Connect with the Study Team
Meet the key contacts from Annovis Bio, Prevail InfoWorks, and our Vendor Partners
Gain Insights
Learn more about the study drug, buntanetap, the protocol, and important details to help you keep the trial running smoothly.
Boost Your Knowledge
Show what you have learned during our Knowledge Checks. Confirm your understanding during Question-and-Answer sessions.
Breaking Barriers In Brain Health
Key Takeaways
Annovis Bio is dedicated to creating treatments that restore cognitive function by targeting multiple neurotoxic proteins simultaneously. This webinar provides key information on Alzheimer’s clinical trials.
01
Mechanism of Action
Buntanetap lowers levels of neurotoxic proteins, including the proteins that cause plaques and tangles in the brain in Alzheimer’s Disease.
02
Protocol Details
Consent process, multi-step screening, treatment to end of study: the ins and outs of the protocol will be explained.
03
Vendor Partner Trainings
Learn more about eCOA, Central Labs, and Central Imaging directly from our Vendor Partners.
04
Systems Trainings
See demos of our EDC, IRT, and the Single Interface that allows you to log in once to access the tools you need.
Speakers
Dr Maria Maccecchini
President & CEO
Dr. Maccecchini founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases. She was partner and director of two angel groups, Robin Hood Ventures and MidAtlantic Angel Group; Founder and CEO of Symphony Pharmaceuticals/Annovis a biotech company that sold in 2001 to Transgenomic; General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head Molecular Biology Mallinckrodt
Cheng Fang
Senior VP of Research and Development
Dr. Fang is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases with broad scientific knowledge and hands-on experience. She has a successful track record of scientific publications and contributions. Dr. Fang has deep drug development knowledge with both pre-clinical and clinical development experience.
Melissa A Gaines
Senior Vice President, Clinical Operations
Ms. Gaines is an accomplished clinical research professional with over 20 years’ experience garnered from positions held in academia, contract research organizations and pharmaceutical companies. She has proven abilities in monitoring and management of Phase I to Phase IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications.
Dr Matthew Peterson
Senior Clinical Scientist
My research passion is using science, engineering, and technology to solve clinical and medical problems to improve patient outcomes. Results driven, detail-oriented, team leader with strong communication skills. Extensive experience with study design, protocol development, real-world evidence, data analytics, peer-reviewed publications, startup and execution of domestic and international clinical studies, CRO selection and management, and EU Medical Device Regulation. Managed studies with respect to FDA, ICH, and GCP guidelines, ISO 14155, and EU MDR regulations.
Sarah MacCallum
Director, Clinical Operations
Dr. Maccecchini founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases.
FAQs
Here are some frequently asked questions about our upcoming events.
If you are experiencing any issues registering, please email our event team at [email protected]
How do I sign up for the event?
Complete the registration form at the top of this page and we’ll send you log in details.
When will the webinar take place?
The webinar takes place on Tuesday 25th February 2025. Detailed start times and agenda will be communicated to you closer to the event.
How do I join the webinar?
Join the webinar by clicking on the link we send you, this will open your browser – we recommend using Google Chrome for the best experience, but any modern browser will work.
Is there a cost associated with joining this event?
No, this event is completely free to attend.
Will there be opportunities to ask questions during the webinar?
Yes, there will interactive Polling and Q&A sessions where everyone can ask questions.
Will recordings of the presentations be available after the webinar?
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.